focus -WSS

focus

author：explore 2025-09-30 17:44:36 - browse：79

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Living with Hashimoto's and celiac disease, and med school, too

hotspot

WSS

Victims of gun violence feel impacts long after bullet wound

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Ambulance rides for just $100? Advisers want major billing fixes

White House calls on federal agencies to crack down on AI abuses

Medicare will require more price transparency from hospitals

FDA approves Recor Medical high blood pressure device

knowledge

focus

focus

In Memoriam: Notable people who died in 2023

Listen: Racing for gene therapy & a pioneering approval

Apple is now the first public company to be valued at $3 trillion

Will General Catalyst be the first of many hospital takeovers?

Hepatitis C has a cure — but many Americans still lack access to it

Beware the threat of staffing cuts at the CDC

Apple is now the first public company to be valued at $3 trillion

Hilary expected to bring catastrophic, life

ChatGPT in medicine: STAT answers readers' burning questions

More doctors should go into startup world

leisure time

Removing probiotics from the NICU could threaten preemies' health

STAT Executive Editor Rick Berke on STAT's 8th birthday

Biotech incubator Curie.Bio graduates its first startup

Liz Cheney makes 1st public comment since Trump's election interference indictments

As Maui death toll rises, number of missing remains unclear

The boys, now 6, who are gene therapy’s ‘edge case’ problem

hotspot

hotspot

focus

hotspot